28 Nov 2017 12:03
28 November 2017
Result of AGM
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, held its Annual General Meeting ("AGM") at 10.00am today. All resolutions were passed.
At the meeting, Peter Allen, Clinigen's Chairman reiterated that the Group is well positioned to deliver another good year of progress, as set out at the recent full year results.
The slides from the presentation given by the Group will be made available on Clinigen's website www.clinigengroup.com.
- Ends-
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer Martin Abell, Group Chief Financial Officer |
|
Matt Parrish, Head of Investor Relations |
|
|
|
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser)James Black / Tom Ballard (Corporate Broking) |
|
|
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas / Jack Wood |
|
|
|
Instinctif Partners (media relations) | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com
CLIN.L (CLIN)